PDSB earnings date and last-quarter result: next report 2026-08-12, last quarter beat, P/E -1.07. Updated 2026-07-23.
PDS Biotechnology (PDSB) Research Hub
PDS Biotechnology (PDSB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.07 USD (-3.60%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.07, market cap 0.04B. This hub links to the full technical, earnings and options research available for PDSB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.07 USD (-3.60%) |
| 52-week range | 0.195 USD – 1.79 USD |
| Trend regime | Range |
| 14-day RSI | 50.5 (Neutral) |
| Trailing P/E | -1.07 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for PDSB
Covered Call on PDSB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PDSB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PDSB: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
PDSB technical analysis: range, last 1.07 USD, RSI 50.5, 52w range 0.195 USD–1.79 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PDSB in?
PDS Biotechnology (PDSB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PDSB in an uptrend or downtrend?
As of 2026-10-26, PDSB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PDSB's trailing P/E ratio?
PDSB's trailing P/E is -1.07, with a market cap of 0.04B. See the earnings research page for full valuation detail.
When does PDSB next report earnings?
PDSB is next scheduled to report earnings on 2026-08-12.